10-Q: Leidos Holdings Reports Strong Second Quarter 2024 Results Driven by Health & Civil Segment

Leidos Holdings, Inc. reported a significant increase in revenue and operating income for the second quarter of 2024, primarily driven by the Health & Civil segment.

Summary

• Leidos Holdings, Inc. reported a revenue of $4.132 billion for the three months ended June 28, 2024, compared to $3.838 billion for the same period last year, representing a 7.7% increase.
• Operating income for the quarter was $475 million, a substantial increase from $331 million in the prior year, marking a 43.5% rise.
• Net income attributable to Leidos common stockholders was $322 million, up from $207 million in the same quarter of the previous year.
• The company's diluted earnings per share (EPS) increased to $2.37 from $1.50 year-over-year.
• For the six months ended June 28, 2024, revenue reached $8.107 billion, a 7.6% increase from $7.537 billion in the prior year.
• Operating income for the first six months of 2024 was $890 million, compared to $596 million in the same period of 2023, a 49.3% increase.
• Net income attributable to Leidos common stockholders for the first six months was $606 million, up from $369 million in the prior year.
• Diluted EPS for the six-month period was $4.42, compared to $2.67 in the prior year.
• The company's remaining performance obligations (RPO) stood at $13.8 billion as of June 28, 2024, with approximately 63% expected to be recognized over the next 12 months and 79% over the next 24 months.
• Net bookings for the three and six months ended June 28, 2024, were $4.0 billion and $7.7 billion, respectively, compared to $2.9 billion and $5.9 billion for the same periods in 2023.

Sentiment

Score: 8

Explanation: The document presents a strong financial performance with significant growth in revenue and profitability, particularly in the Health & Civil segment. While there are some concerns regarding international operations and tax rates, the overall tone is positive, indicating a healthy outlook for the company.

Positives

• The Health & Civil segment demonstrated exceptional growth, driving overall profitability.
• The company experienced a significant increase in operating income across multiple segments.
• Leidos' backlog remains strong, indicating future revenue potential.
• The company's earnings per share showed substantial improvement.
• The company has a strong cash position and access to additional credit if needed.
• Net bookings increased significantly compared to the same period last year.
• The company is actively repurchasing shares, indicating confidence in its future performance.

Negatives

• The Commercial & International segment experienced an operating loss of $11 million for the quarter.
• The Commercial & International segment's operating income decreased by 51.1% for the six months ended June 28, 2024.
• The company recorded write-downs on programs within its UK operations due to cost increases and schedule delays.
• The effective tax rate increased for both the three and six months ended June 28, 2024, primarily due to a reduced benefit in federal research tax credits.

Risks

• The company is subject to ongoing government investigations and reviews, which could result in penalties and reputational damage.
• The company's international operations expose it to regulatory and geopolitical risks.
• Failure to pass the U.S. appropriations bills or a continuing resolution by September 30, 2024, could result in a federal government shutdown.
• Changes in international trade policies, including higher tariffs, may increase procurement costs.
• The company's operations rely heavily on government contracts, making it vulnerable to changes in government spending.
• The company's goodwill could be impaired if there are significant unfavorable changes to forecasted cash flows, revenue, or cost of capital.

Future Outlook

The company anticipates being able to meet its liquidity needs for the next 12 months through cash generated from operations, available cash balances, borrowings from its commercial paper program, and if needed, sales of accounts receivable and borrowings from its revolving credit facility.

Management Comments

• Management believes that the company has adequately reserved for potential adjustments from audits or reviews of contract costs.
• Management does not believe that outstanding performance guarantees and cross-indemnity agreements will have a material effect on the company's liquidity, capital expenditures, or financial condition.

Industry Context

Leidos operates in the government contracting industry, which is heavily influenced by government spending and budget priorities. The company's performance is tied to the U.S. government's focus on national security, homeland security, and intelligence. The realignment of the company's business segments reflects a strategic move to better align with market demands and customer needs. The company's international operations expose it to global market trends and geopolitical risks.

Comparison to Industry Standards

• Leidos' revenue growth of 7.7% in Q2 2024 is solid compared to other large government contractors, such as General Dynamics (GD) and Lockheed Martin (LMT), which have seen more modest growth in recent quarters.
• The significant increase in operating income, particularly in the Health & Civil segment, suggests strong operational efficiency and project management, which is a key differentiator in the industry.
• The company's backlog of $36.487 billion is substantial, indicating a healthy pipeline of future work, which is comparable to other major players in the sector.
• The company's focus on digital modernization and cybersecurity aligns with current industry trends and government priorities, positioning it well for future growth.
• The write-downs in the UK operations highlight the risks associated with international projects, which is a common challenge for companies in this sector, such as BAE Systems (BAESY).
• The company's effective tax rate increase is a concern, as it could impact future profitability, and should be monitored against industry benchmarks.

Legal Proceedings

• The company is involved in various claims and lawsuits arising in the normal conduct of its business.
• The company is subject to investigations and reviews relating to compliance with various laws and regulations.
• The company is conducting an internal investigation related to international operations and has self-reported to the Department of Justice and the Securities and Exchange Commission.
• The company received a Federal Grand Jury Subpoena related to a criminal investigation by the U.S. Attorneys Office for the Southern District of California.
• The company received a Federal Grand Jury Subpoena in connection with a criminal investigation being conducted by the U.S. Department of Justice Antitrust Division.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and share repurchases.
• Employees may see increased job security and potential for career growth due to the company's strong performance.
• Customers will benefit from the company's continued investment in technology and innovation.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors will be reassured by the company's strong financial position and ability to meet its obligations.

Next Steps

• The company will continue to evaluate the impact of the new segment reporting structure.
• The company will monitor the ongoing government investigations and reviews.
• The company will continue to evaluate the impact of higher tariffs on imported goods.
• The company will continue to evaluate the impact of the Pillar Two legislation.
• The company will continue to monitor the U.S. government budget process and potential government shutdown.

Key Dates

Keywords

Leidos, Government Contracts, Defense, Health, Technology, National Security, Operating Income, Revenue, Backlog, EPS, Financial Results, Cybersecurity, Digital Modernization, International Operations